Compare TTMI & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTMI | RDY |
|---|---|---|
| Founded | 1978 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.6B |
| IPO Year | 2000 | 2001 |
| Metric | TTMI | RDY |
|---|---|---|
| Price | $87.66 | $14.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $98.50 | $16.90 |
| AVG Volume (30 Days) | ★ 1.8M | 1.6M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.50% |
| EPS Growth | ★ 211.11 | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $2,906,345,000.00 | N/A |
| Revenue This Year | $19.46 | $7.50 |
| Revenue Next Year | $17.05 | $2.96 |
| P/E Ratio | $58.84 | ★ $18.67 |
| Revenue Growth | ★ 18.98 | N/A |
| 52 Week Low | $16.55 | $12.26 |
| 52 Week High | $113.46 | $16.17 |
| Indicator | TTMI | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 54.75 |
| Support Level | $87.28 | $14.20 |
| Resistance Level | $110.38 | $14.66 |
| Average True Range (ATR) | 7.33 | 0.25 |
| MACD | -1.69 | -0.04 |
| Stochastic Oscillator | 0.02 | 45.06 |
TTM Technologies Inc manufactures technology products, including mission systems, RF components, RF/microwave assemblies, and advanced interconnect products such as PCBs and substrates. It operates through three segments: A&D, Commercial, and RF&S Components. The A&D segment supports aerospace and defense missions with PCBs, assemblies, microelectronics, and integrated systems. The Commercial segment, generating the majority of revenue, serves automotive, medical, industrial, and data center markets. The RF&S Components segment provides TTM-designed RF components and COTS products. The Company's revenues come from PCBs, engineered systems, and long-term contracts for intelligence, surveillance, and communications solutions.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.